Abstract:Background/Objectives: Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic disease of the liver that symptomatically can present with pruritus and fatigue. Its established first- and second-line therapies are ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) although they provide limited symptom management. Liver transplantation offers a potentially curative therapeutic option in refractory cases progressing to cirrhosis. Novel research published after the current guidelines highlights the importance of providing an up-to-date analysis of treatment options available. Methods: In this study, we conducted a literature search using Pubmed, Ovid Medline, and SCOPUS to provide a narrative review of first-line, second-line, and emerging therapies in PBC. Results: UDCA has been well established as a long-term, safe therapy within the literature although it is possible that treatment dosage can be further optimised in refractory patients. It has a favourable side effect profile. Despite improving biochemical markers, histopathological profile, and overall outcomes, up to 30–40% of patients are refractory to it. Age and sex are highlighted as independent indicators of non-responsiveness. This necessitates effective second-line therapies. Future trials could aim to investigate UDCA as a co-first-line therapy. Further supporting results for OCA were found in the interim extension trial of the seminal POISE study. The long-term phase 4 COBOLT trial is still awaiting results to further assess the complications, adherence, and potential adverse effects. It is a viable option in UDCA-refractory patients. The high incidence rate of dose-related pruritis indicates that alternative second-line options are needed. Bezafibrate is an off-label antilipemic agent that shows promise as a prospective second-line therapy option. The landmark BEZURSO trial alleviated some efficacy and safety concerns, but it remains associated with elevated serum creatinine; thus, it should be considered with caution. Other prospective second-line therapies are budesonide, triple therapy, and novel agents such as seladelpar and elafibranor. Conclusions: UDCA should remain the treatment of choice for PBC, though perhaps not as monotherapy. With further investigation, BF shows promise as a new second-line therapy alongside OCA, which it may outperform.

S2049 Predictors of Major Adverse Cardiovascular Events in Patients With Primary Biliary Cholangitis

S1996 Statins Protect Against Major Liver Events in Patients With Primary Biliary Cholangitis

Clinical Analysis of Primary Biliary Cirrhosis: a Report of 31 Cases

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

Factors associated with progression and outcomes of primary biliary cholangitis: A cohort study, 2010-2019

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid

New Treatment Paradigms in Primary Biliary Cholangitis

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis

Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis

[Primary biliary cholangitis. Experience in 179 patients]

Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.

Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value

Comorbidities, mortality and metabolic profile in individuals with primary biliary cholangitis—A Phenome‐Wide‐Association‐Study

Chronic Complications of Cholestasis: Evaluation and Management

Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape

Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis

Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis

Novel therapeutic targets in primary biliary cirrhosis

Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy